Targeting the hallmarks of cancer with therapy-induced endoplasmic reticulum (ER) stress

Molecular and Cellular Oncology

Volumn 2, Issue 1, 2015, Pages

  Garg, Abhishek D ^a   Maes, Hannelore ^a   van Vliet, Alexander R ^a   Agostinis, Patrizia ^a  

^a LABORATORY OF MOLECULAR AND CELLULAR SIGNALING   (Belgium)

Author keywords

angiogenesis; anticancer immunity; autophagy; cancer hallmarks; cancer therapy; endoplasmic reticulum; ER stress; immunogenic cell death; immunosurveillance; inflammation; invasion and metastasis; unfolded protein response (UPR)

Indexed keywords

EID: 84938206702     PISSN: None     EISSN: 23723556     Source Type: Journal    
DOI: 10.4161/23723556.2014.975089     Document Type: Review

References (191)

1. Schuldiner M, Schwappach B. From rags to riches—the history of the endoplasmic reticulum. Biochim Biophys Acta 2013; 1833:2389-91; PMID:23500901; http://dx.doi.org/10.1016/j.bbamcr.2013.03.005
2. Palade GE, Siekevitz P. Liver microsomes; an integrated morphological and biochemical study. J Biophys Biochem Cytol 1956; 2:171-200; PMID:13319380; http://dx.doi.org/10.1083/jcb.2.2.171
3. Porter KR, Blum J. A study in microtomy for electron microscopy. Anat Rec 1953; 117:685-710; PMID:13124776; http://dx.doi.org/10.1002/ar.1091170403
4. Palade GE, Siekevitz P. Pancreatic microsomes; an integrated morphological and biochemical study. J Biophys Biochem Cytol 1956; 2:671-90; PMID:13398437; http://dx.doi.org/10.1083/jcb.2.6.671
5. Hasselbach W, Makinose M. [The calcium pump of the “relaxing granules” of muscle and its dependence on ATP-splitting]. Biochem Z 1961; 333:518-28; PMID:13712164
6. Ebashi S, Lipmann F. Adenosine triphosphate-linked concentration of calcium ions in a particulate fraction of rabbit muscle. J Cell Biol 1962; 14:389-400; PMID:19866605; http://dx.doi.org/10.1083/jcb.14.3.389
7. Stein O, Stein Y. Lipid synthesis, intracellular transport, and secretion. II. Electron microscopic radioautographic study of the mouse lactating mammary gland. J Cell Biol 1967; 34:251-63; PMID:6033535; http://dx.doi.org/10.1083/jcb.34.1.251
8. Blobel G, Sabatini DD. Ribosome/membrane interaction in eukaryotic cells. Biomembranes 1971; 2:193-5; http://dx.doi.org/10.1007/978-1-4684-3330-2_16
9. Blobel G, Dobberstein B. Transfer of proteins across membranes. II. Reconstitution of functional rough microsomes from heterologous components. J Cell Biol 1975; 67:852-62; PMID:811672; http://dx.doi.org/10.1083/jcb.67.3.852
10. Blobel G, Walter P, Chang CN, Goldman BM, Erickson AH, Lingappa VR. Translocation of proteins across membranes: the signal hypothesis and beyond. Symp Soc Exp Biol 1979; 33:9-36; PMID:524275
11. Gilmore R, Walter P, Blobel G. Protein translocation across the endoplasmic reticulum. II. Isolation and characterization of the signal recognition particle receptor. J Cell Biol 1982; 95:470-7; PMID:6292236; http://dx.doi.org/10.1083/jcb.95.2.470
12. Walter P, Blobel G. Signal recognition particle contains a 7S RNA essential for protein translocation across the endoplasmic reticulum. Nature 1982; 299:691-8; PMID:6181418; http://dx.doi.org/10.1038/299691a0
13. Ostwald TJ, MacLennan DH. Isolation of a high affinity calcium-binding protein from sarcoplasmic reticulum. J Biol Chem 1974; 249:974-9; PMID:4272851
14. Munro S, Pelham HR. A C-terminal signal prevents secretion of luminal ER proteins. Cell 1987; 48:899-907; PMID:3545499; http://dx.doi.org/10.1016/0092-8674(87)90086-9
15. Lippincott-Schwartz J, Bonifacino JS, Yuan LC, Klausner RD. Degradation from the endoplasmic reticulum: disposing of newly synthesized proteins. Cell 1988; 54:209-20; PMID:3292055; http://dx.doi.org/10.1016/0092-8674(88)90553-3
16. Vembar SS, Brodsky JL. One step at a time: endoplasmic reticulum-associated degradation. Nat Rev Mol Cell Biol 2008; 9:944-57; PMID:19002207; http://dx.doi.org/10.1038/nrm2546
17. McCracken AA, Brodsky JL. Assembly of ER-associated protein degradation in vitro: dependence on cytosol, calnexin, and ATP. J Cell Biol 1996; 132:291-8; PMID:8636208; http://dx.doi.org/10.1083/jcb.132.3.291
18. Mori K, Sant A, Kohno K, Normington K, Gething MJ, Sambrook JF. A 22 bp cis-acting element is necessary and sufficient for the induction of the yeast KAR2 (BiP) gene by unfolded proteins. EMBO J 1992; 11:2583-93; PMID:1628622
19. Cox JS, Shamu CE, Walter P. Transcriptional induction of genes encoding endoplasmic reticulum resident proteins requires a transmembrane protein kinase. Cell 1993; 73:1197-206; PMID:8513503; http://dx.doi.org/10.1016/0092-8674(93)90648-A
20. Mori K, Ma W, Gething MJ, Sambrook J. A transmembrane protein with a cdc2+/CDC28-related kinase activity is required for signaling from the ER to the nucleus. Cell 1993; 74:743-56; PMID:8358794; http://dx.doi.org/10.1016/0092-8674(93)90521-Q
21. Harding HP, Zhang Y, Ron D. Protein translation and folding are coupled by an endoplasmic-reticulum-resident kinase. Nature 1999; 397:271-4; PMID:9930704; http://dx.doi.org/10.1038/16729
22. Shi Y, Vattem KM, Sood R, An J, Liang J, Stramm L, Wek RC. Identification and characterization of pancreatic eukaryotic initiation factor 2 alpha-subunit kinase, PEK, involved in translational control. Mol Cell Biol 1998; 18:7499-509; PMID:9819435
23. Harding HP, Zhang Y, Bertolotti A, Zeng H, Ron D. Perk is essential for translational regulation and cell survival during the unfolded protein response. Mol Cell 2000; 5:897-904; PMID:10882126; http://dx.doi.org/10.1016/S1097-2765(00)80330-5
24. Haze K, Yoshida H, Yanagi H, Yura T, Mori K. Mammalian transcription factor ATF6 is synthesized as a transmembrane protein and activated by proteolysis in response to endoplasmic reticulum stress. Mol Biol Cell 1999; 10:3787-99; PMID:10564271; http://dx.doi.org/10.1091/mbc.10.11.3787
25. Clarke HJ, Chambers JE, Liniker E, Marciniak SJ. Endoplasmic reticulum stress in malignancy. Cancer cell 2014; 25:563-73; PMID:24823636; http://dx.doi.org/10.1016/j.ccr.2014.03.015
26. Hetz C, Chevet E, Harding HP. Targeting the unfolded protein response in disease. Nat Rev Drug Discov 2013; 12:703-19; PMID:23989796; http://dx.doi.org/10.1038/nrd3976
27. Woehlbier U, Hetz C. Modulating stress responses by the UPRosome: a matter of life and death. Trends Biochem Sci 2011; 36:329-37; PMID:21482118; http://dx.doi.org/10.1016/j.tibs.2011.03.001
28. Xu C, Bailly-Maitre B, Reed JC. Endoplasmic reticulum stress: cell life and death decisions. J Clin Invest 2005; 115:2656-64; PMID:16200199; http://dx.doi.org/10.1172/JCI26373
29. Garg AD, Kaczmarek A, Krysko O, Vandenabeele P, Krysko DV, Agostinis P. ER stress-induced inflammation: does it aid or impede disease progression? Trends Mol Med 2012; 18:589-98; PMID:22883813; http://dx.doi.org/10.1016/j.molmed.2012.06.010
30. Marciniak SJ, Yun CY, Oyadomari S, Novoa I, Zhang Y, Jungreis R, Nagata K, Harding HP, Ron D. CHOP induces death by promoting protein synthesis and oxidation in the stressed endoplasmic reticulum. Genes Dev 2004; 18:3066-77; PMID:15601821; http://dx.doi.org/10.1101/gad.1250704
31. Ogata M, Hino S, Saito A, Morikawa K, Kondo S, Kanemoto S, Murakami T, Taniguchi M, Tanii I, Yoshinaga K, et al. Autophagy is activated for cell survival after endoplasmic reticulum stress. Mol Cell Biol 2006; 26:9220-31; PMID:17030611; http://dx.doi.org/10.1128/MCB.01453-06
32. Bernales S, McDonald KL, Walter P. Autophagy counterbalances endoplasmic reticulum expansion during the unfolded protein response. PLoS Biol 2006; 4:e423; PMID:17132049
33. Grimm S. The ER-mitochondria interface: the social network of cell death. Biochim Biophys Acta 2012; 1823:327-34; PMID:22182703; http://dx.doi.org/10.1016/j.bbamcr.2011.11.018
34. Naon D, Scorrano L. At the right distance: ER-mitochondria juxtaposition in cell life and death. Biochim Biophys Acta 2014; 1843:2184-94; PMID:24875902; http://dx.doi.org/10.1016/j.bbamcr.2014.05.011
35. Verfaillie T, Rubio N, Garg AD, Bultynck G, Rizzuto R, Decuypere JP, Piette J, Linehan C, Gupta S, Samali A, et al. PERK is required at the ER-mitochondrial contact sites to convey apoptosis after ROS-based ER stress. Cell Death Differ 2012; 19:1880-91; PMID:22705852; http://dx.doi.org/10.1038/cdd.2012.74
36. Ma Y, Hendershot LM. The role of the unfolded protein response in tumour development: friend or foe? Nat Rev Cancer 2004; 4:966-77; PMID:15573118; http://dx.doi.org/10.1038/nrc1505
37. Jamora C, Dennert G, Lee AS. Inhibition of tumor progression by suppression of stress protein GRP78/BiP induction in fibrosarcoma B/C10ME. Proc Natl Acad Sci U S A 1996; 93:7690-4; PMID:8755537; http://dx.doi.org/10.1073/pnas.93.15.7690
38. Ozawa K, Tsukamoto Y, Hori O, Kitao Y, Yanagi H, Stern DM, Ogawa S. Regulation of tumor angiogenesis by oxygen-regulated protein 150, an inducible endoplasmic reticulum chaperone. Cancer Res 2001; 61:4206-13; PMID:11358846
39. Romero-Ramirez L, Cao H, Nelson D, Hammond E, Lee AH, Yoshida H, Mori K, Glimcher LH, Denko NC, Giaccia AJ, et al. XBP1 is essential for survival under hypoxic conditions and is required for tumor growth. Cancer Res 2004; 64:5943-7; PMID:15342372; http://dx.doi.org/10.1158/0008-5472.CAN-04-1606
40. Verfaillie T, Garg AD, Agostinis P. Targeting ER stress induced apoptosis and inflammation in cancer. Cancer Lett 2013; 332:249-64; PMID:20732741; http://dx.doi.org/10.1016/j.canlet.2010.07.016
41. Moenner M, Pluquet O, Bouchecareilh M, Chevet E. Integrated endoplasmic reticulum stress responses in cancer. Cancer Res 2007; 67:10631-4; PMID:18006802; http://dx.doi.org/10.1158/0008-5472.CAN-07-1705
42. Dejeans N, Manie S, Hetz C, Bard F, Hupp T, Agostinis P, Samali A, Chevet E. Addicted to secrete—novel concepts and targets in cancer therapy. Trends Mol Med 2014; 20:242-50; PMID:24456621; http://dx.doi.org/10.1016/j.molmed.2013.12.003
43. Auf G, Jabouille A, Guerit S, Pineau R, Delugin M, Bouchecareilh M, Magnin N, Favereaux A, Maitre M, Gaiser T, et al. Inositol-requiring enzyme 1alpha is a key regulator of angiogenesis and invasion in malignant glioma. Proc Natl Acad Sci U S A 2010; 107:15553-8; PMID:20702765; http://dx.doi.org/10.1073/pnas.0914072107
44. Bi M, Naczki C, Koritzinsky M, Fels D, Blais J, Hu N, Harding H, Novoa I, Varia M, Raleigh J, et al. ER stress-regulated translation increases tolerance to extreme hypoxia and promotes tumor growth. EMBO J 2005; 24:3470-81; PMID:16148948; http://dx.doi.org/10.1038/sj.emboj.7600777
45. Blais JD, Addison CL, Edge R, Falls T, Zhao H, Wary K, Koumenis C, Harding HP, Ron D, Holcik M, et al. Perk-dependent translational regulation promotes tumor cell adaptation and angiogenesis in response to hypoxic stress. Mol Cell Biol 2006; 26:9517-32; PMID:17030613; http://dx.doi.org/10.1128/MCB.01145-06
46. Bobrovnikova-Marjon E, Grigoriadou C, Pytel D, Zhang F, Ye J, Koumenis C, Cavener D, Diehl JA. PERK promotes cancer cell proliferation and tumor growth by limiting oxidative DNA damage. Oncogene 2010; 29:3881-95; PMID:20453876; http://dx.doi.org/10.1038/onc.2010.153
47. Drogat B, Auguste P, Nguyen DT, Bouchecareilh M, Pineau R, Nalbantoglu J, Kaufman RJ, Chevet E, Bikfalvi A, Moenner M. IRE1 signaling is essential for ischemia-induced vascular endothelial growth factor-A expression and contributes to angiogenesis and tumor growth in vivo. Cancer Res 2007; 67:6700-7; PMID:17638880; http://dx.doi.org/10.1158/0008-5472.CAN-06-3235
48. Huber AL, Lebeau J, Guillaumot P, Petrilli V, Malek M, Chilloux J, Fauvet F, Payen L, Kfoury A, Renno T, et al. p58(IPK)-mediated attenuation of the proapoptotic PERK-CHOP pathway allows malignant progression upon low glucose. Mol Cell 2013; 49:1049-59; PMID:23395000; http://dx.doi.org/10.1016/j.molcel.2013.01.009
49. Wang Y, Alam GN, Ning Y, Visioli F, Dong Z, Nor JE, Polverini PJ. The unfolded protein response induces the angiogenic switch in human tumor cells through the PERK/ATF4 pathway. Cancer Res 2012; 72:5396-406; PMID:22915762; http://dx.doi.org/10.1158/0008-5472.CAN-12-0474
50. Gardai SJ, McPhillips KA, Frasch SC, Janssen WJ, Starefeldt A, Murphy-Ullrich JE, Bratton DL, Oldenborg PA, Michalak M, Henson PM. Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell 2005; 123:321-34; PMID:16239148; http://dx.doi.org/10.1016/j.cell.2005.08.032
51. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, Castedo M, Mignot G, Panaretakis T, Casares N, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007; 13:54-61; PMID:17187072; http://dx.doi.org/10.1038/nm1523
52. Galluzzi L, Kepp O, Kroemer G. Enlightening the impact of immunogenic cell death in photodynamic cancer therapy. EMBO J 2012; 31:1055-7; MID:22252132; http://dx.doi.org/10.1038/emboj.2012.2
53. Zitvogel L, Kepp O, Senovilla L, Menger L, Chaput N, Kroemer G. Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway. Clin Cancer Res 2010; 16:3100-4; PMID:20421432; http://dx.doi.org/10.1158/1078-0432.CCR-09-2891
54. Garg AD, Agostinis P. ER stress, autophagy and immunogenic cell death in photodynamic therapy-induced anti-cancer immune responses. Photochem Photobiol Sci 2014; 13:474-87; PMID:24493131; http://dx.doi.org/10.1039/c3pp50333j
55. Garg AD, Krysko DV, Vandenabeele P, Agostinis P. Hypericin-based photodynamic therapy induces surface exposure of damage-associated molecular patterns like HSP70 and calreticulin. Cancer Immunol Immunother 2012; 61:215-21; PMID:22193987; http://dx.doi.org/10.1007/s00262-011-1184-2
56. Garg AD, Krysko DV, Verfaillie T, Kaczmarek A, Ferreira GB, Marysael T, Rubio N, Firczuk M, Mathieu C, Roebroek AJ, et al. A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. EMBO J 2012; 31:1062-79; PMID:22252128
57. Panaretakis T, Kepp O, Brockmeier U, Tesniere A, Bjorklund AC, Chapman DC, Durchschlag M, Joza N, Pierron G, van Endert P, et al. Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J 2009; 28:578-90; PMID:19165151; http://dx.doi.org/10.1038/emboj.2009.1
58. Axten JM, Medina JR, Feng Y, Shu A, Romeril SP, Grant SW, Li WH, Heerding DA, Minthorn E, Mencken T, et al. Discovery of 7-methyl-5-(1-{[3-(trifluoromethyl)phenyl]acetyl}-2,3-dihydro-1H-indol-5-yl)-7H-p yrrolo[2,3-d]pyrimidin-4-amine (GSK2606414), a potent and selective first-in-class inhibitor of protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK). J Med Chem 2012; 55:7193-207; http://dx.doi.org/10.1021/jm300713s
59. Atkins C, Liu Q, Minthorn E, Zhang SY, Figueroa DJ, Moss K, Stanley TB, Sanders B, Goetz A, Gaul N, et al. Characterization of a novel PERK kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res 2013; 73:1993-2002; PMID:23333938; http://dx.doi.org/10.1158/0008-5472.CAN-12-3109
60. Mimura N, Fulciniti M, Gorgun G, Tai YT, Cirstea D, Santo L, Hu Y, Fabre C, Minami J, Ohguchi H, et al. Blockade of XBP1 splicing by inhibition of IRE1alpha is a promising therapeutic option in multiple myeloma. Blood 2012; 119:5772-81; PMID:22538852; http://dx.doi.org/10.1182/blood-2011-07-366633
61. Papandreou I, Denko NC, Olson M, Van Melckebeke H, Lust S, Tam A, Solow-Cordero DE, Bouley DM, Offner F, Niwa M, et al. Identification of an Ire1alpha endonuclease specific inhibitor with cytotoxic activity against human multiple myeloma. Blood 2011; 117:1311-4; PMID:21081713; http://dx.doi.org/10.1182/blood-2010-08-303099
62. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348:2609-17; PMID:12826635; http://dx.doi.org/10.1056/NEJMoa030288
63. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646-74; PMID:21376230; http://dx.doi.org/10.1016/j.cell.2011.02.013
64. Maes H, Rubio N, Garg AD, Agostinis P. Autophagy: shaping the tumor microenvironment and therapeutic response. Trends Mol Med 2013; 19:428-46; PMID:23714574; http://dx.doi.org/10.1016/j.molmed.2013.04.005
65. Schafer M, Werner S. Cancer as an overhealing wound: an old hypothesis revisited. Nat Rev Mol Cell Biol 2008; 9:628-38; PMID:18628784; http://dx.doi.org/10.1038/nrm2455
66. Sonnenschein C, Soto AM. The aging of the 2000 and 2011 hallmarks of cancer reviews: a critique. J Biosci 2013; 38:651-63; PMID:23938395; http://dx.doi.org/10.1007/s12038-013-9335-6
67. Lazebnik Y. What are the hallmarks of cancer? Nat Rev Cancer 2010; 10:232-3; PMID:20355252; http://dx.doi.org/10.1038/nrc2827
68. Speeckaert R, van Geel N, Vermaelen KV, Lambert J, Van Gele M, Speeckaert MM, Brochez L. Immune reactions in benign and malignant melanocytic lesions: lessons for immunotherapy. Pigment Cell Melanoma Res 2011; 24:334-44; PMID:21029398; http://dx.doi.org/10.1111/j.1755-148X.2010.00799.x
69. Darling NJ, Cook SJ. The role of MAPK signalling pathways in the response to endoplasmic reticulum stress. Biochim Biophys Acta 2014; 1843:2150-63; PMID:24440275; http://dx.doi.org/10.1016/j.bbamcr.2014.01.009
70. Feng R, Zhai WL, Yang HY, Jin H, Zhang QX. Induction of ER stress protects gastric cancer cells against apoptosis induced by cisplatin and doxorubicin through activation of p38 MAPK. Biochem Biophys Res Commun 2011; 406:299-304; PMID:21320468; http://dx.doi.org/10.1016/j.bbrc.2011.02.036
71. Fan L, Song B, Sun G, Ma T, Zhong F, Wei W. Endoplasmic reticulum stress-induced resistance to doxorubicin is reversed by paeonol treatment in human hepatocellular carcinoma cells. PLoS One 2013; 8:e62627; PMID:23658755; http://dx.doi.org/10.1371/journal.pone.0062627
72. Dai R, Chen R, Li H. Cross-talk between PI3K/Akt and MEK/ERK pathways mediates endoplasmic reticulum stress-induced cell cycle progression and cell death in human hepatocellular carcinoma cells. Int J Oncol 2009; 34:1749-57; PMID:19424594
73. Jiang CC, Yang F, Thorne RF, Zhu BK, Hersey P, Zhang XD. Human melanoma cells under endoplasmic reticulum stress acquire resistance to microtubule-targeting drugs through XBP-1-mediated activation of Akt. Neoplasia 2009; 11:436-47; PMID:19412428
74. Bian J, Wang K, Kong X, Liu H, Chen F, Hu M, Zhang X, Jiao X, Ge B, Wu Y, et al. Caspase- and p38-MAPK-dependent induction of apoptosis in A549 lung cancer cells by Newcastle disease virus. Arch Virol 2011; 156:1335-44; PMID:21625975; http://dx.doi.org/10.1007/s00705-011-0987-y
75. Assefa Z, Vantieghem A, Declercq W, Vandenabeele P, Vandenheede JR, Merlevede W, de Witte P, Agostinis P. The activation of the c-Jun N-terminal kinase and p38 mitogen-activated protein kinase signaling pathways protects HeLa cells from apoptosis following photodynamic therapy with hypericin. J Biol Chem 1999; 274:8788-96; PMID:10085120; http://dx.doi.org/10.1074/jbc.274.13.8788
76. Dewaele M, Martinet W, Rubio N, Verfaillie T, de Witte PA, Piette J, Agostinis P. Autophagy pathways activated in response to PDT contribute to cell resistance against ROS damage. J Cell Mol Med 2011; 15:1402-14; PMID:20626525; http://dx.doi.org/10.1111/j.1582-4934.2010.01118.x
77. de Witte P, Agostinis P, Van Lint J, Merlevede W, Vandenheede JR. Inhibition of epidermal growth factor receptor tyrosine kinase activity by hypericin. Biochem Pharmacol 1993; 46:1929-36; PMID:8267642; http://dx.doi.org/10.1016/0006-2952(93)90633-8
78. Agostinis P, Vandenbogaerde A, Donella-Deana A, Pinna LA, Lee KT, Goris J, Merlevede W, Vandenheede JR, De Witte P. Photosensitized inhibition of growth factor-regulated protein kinases by hypericin. Biochem Pharmacol 1995; 49:1615-22; PMID:7786302; http://dx.doi.org/10.1016/0006-2952(95)00097-J
79. Shu CW, Sun FC, Cho JH, Lin CC, Liu PF, Chen PY, Chang MD, Fu HW, Lai YK. GRP78 and Raf-1 cooperatively confer resistance to endoplasmic reticulum stress-induced apoptosis. J Cell Physiol 2008; 215:627-35; PMID:18064632; http://dx.doi.org/10.1002/jcp.21340
80. Ma XH, Piao SF, Dey S, McAfee Q, Karakousis G, Villanueva J, Hart LS, Levi S, Hu J, Zhang G, et al. Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma. J Clin Invest 2014; 124:1406-17; PMID:24569374; http://dx.doi.org/10.1172/JCI70454
81. Zhou J, Mao B, Zhou Q, Ding D, Wang M, Guo P, Gao Y, Shay JW, Yuan Z, Cong YS. Endoplasmic reticulum stress activates telomerase. Aging cell 2014; 13:197-200; PMID:24119029; http://dx.doi.org/10.1111/acel.12161
82. Hosoi T, Inoue Y, Nakatsu K, Matsushima N, Kiyose N, Shimamoto A, Tahara H, Ozawa K. TERT attenuated ER stress-induced cell death. Biochem Biophys Res Commun 2014; 447:378-82; PMID:24746472; http://dx.doi.org/10.1016/j.bbrc.2014.04.034
83. Zhu B, Ferry CH, Markell LK, Blazanin N, Glick AB, Gonzalez FJ, Peters JM. The nuclear receptor PPARbeta/delta promotes oncogene-induced cellular senescence through repression of endoplasmic reticulum stress. J Biol Chem 2014:9(29):20102-19; PMID:24898257; http://dx.doi.org/10.1074/jbc.M114.551069
84. Li W, Wang W, Dong H, Li Y, Li L, Han L, Han Z, Wang S, Ma D, Wang H. Cisplatin-induced senescence in ovarian cancer cells is mediated by GRP78. Oncology reports 2014; 31:2525-34; PMID:24756776
85. Sasaki T, Tazawa H, Hasei J, Kunisada T, Yoshida A, Hashimoto Y, Yano S, Yoshida R, Uno F, Kagawa S, et al. Preclinical evaluation of telomerase-specific oncolytic virotherapy for human bone and soft tissue sarcomas. Clin Cancer Res 2011; 17:1828-38; PMID:21325287; http://dx.doi.org/10.1158/1078-0432.CCR-10-2066
86. Lin WH, Yeh SH, Yang WJ, Yeh KH, Fujiwara T, Nii A, Chang SS, Chen PJ. Telomerase-specific oncolytic adenoviral therapy for orthotopic hepatocellular carcinoma in HBx transgenic mice. Int J Cancer 2013; 132:1451-62; PMID:22886913; http://dx.doi.org/10.1002/ijc.27770
87. Liu T, Liang X, Li B, Bjorkholm M, Jia J, Xu D. Telomerase reverse transcriptase inhibition stimulates cyclooxygenase 2 expression in cancer cells and synergizes with celecoxib to exert anti-cancer effects. Br J Cancer 2013; 108:2272-80; PMID:23681187; http://dx.doi.org/10.1038/bjc.2013.208
88. Liu XR, Cai Y, Cao X, Wei RC, Li HL, Zhou XM, Zhang KJ, Wu S, Qian QJ, Cheng B, et al. A new oncolytic adenoviral vector carrying dual tumour suppressor genes shows potent anti-tumour effect. J Cell Mol Med 2012; 16:1298-309; PMID:21794078; http://dx.doi.org/10.1111/j.1582-4934.2011.01396.x
89. Ozen KP, Sahin F, Avci CB, Hisil Y, Gunduz C, Saydam G. Hypericium perforatum extract (St. John's Wort) and hypericin induce apoptosis in leukemic HL-60 cells by effecting h-TERT activity. Turk J Hematol 2007; 24:127-33
90. Gaddameedhi S, Chatterjee S. Association between the unfolded protein response, induced by 2-deoxyglucose, and hypersensitivity to cisplatin: a mechanistic study employing molecular genomics. J Cancer Res Ther 2009; 5 Suppl 1:S61-6; PMID:20009298
91. Yamamori T, Meike S, Nagane M, Yasui H, Inanami O. ER stress suppresses DNA double-strand break repair and sensitizes tumor cells to ionizing radiation by stimulating proteasomal degradation of Rad51. FEBS Lett 2013; 587:3348-53; PMID:24021650; http://dx.doi.org/10.1016/j.febslet.2013.08.030
92. Senovilla L, Vitale I, Martins I, Tailler M, Pailleret C, Michaud M, Galluzzi L, Adjemian S, Kepp O, Niso-Santano M, et al. An immunosurveillance mechanism controls cancer cell ploidy. Science 2012; 337:1678-84; PMID:23019653; http://dx.doi.org/10.1126/science.1224922
93. -2 in G2/M phase-arrested cells following photodynamic therapy with hypericin involves a CDK1-mediated signal and delays the onset of apoptosis. J Biol Chem 2002; 277:37718-31; PMID:12101183; http://dx.doi.org/10.1074/jbc.M204348200
94. Marjon PL, Bobrovnikova-Marjon EV, Abcouwer SF. Expression of the pro-angiogenic factors vascular endothelial growth factor and interleukin-8/CXCL8 by human breast carcinomas is responsive to nutrient deprivation and endoplasmic reticulum stress. Mol Cancer 2004; 3:4; PMID:14738568; http://dx.doi.org/10.1186/1476-4598-3-4
95. Pereira ER, Liao N, Neale GA, Hendershot LM. Transcriptional and post-transcriptional regulation of proangiogenic factors by the unfolded protein response. PLoS One 2010; 5:e12521; PMID:20824063
96. Bota DA, Alexandru D, Keir ST, Bigner D, Vredenburgh J, Friedman HS. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis. J Neurosurg 2013; 119:1415-23; PMID:24093630; http://dx.doi.org/10.3171/2013.7.JNS1323
97. Shukla N, Freeman N, Gadsdon P, Angelini GD, Jeremy JY. Thapsigargin inhibits angiogenesis in the rat isolated aorta: studies on the role of intracellular calcium pools. Cardiovasc Res 2001; 49:681-9; PMID:11166281; http://dx.doi.org/10.1016/S0008-6363(00)00269-8
98. Roccaro AM, Hideshima T, Raje N, Kumar S, Ishitsuka K, Yasui H, Shiraishi N, Ribatti D, Nico B, Vacca A, et al. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res 2006; 66:184-91; PMID:16397231; http://dx.doi.org/10.1158/0008-5472.CAN-05-1195
99. Banerjee A, Lang JY, Hung MC, Sengupta K, Banerjee SK, Baksi K, Banerjee DK. Unfolded protein response is required in nu/nu mice microvasculature for treating breast tumor with tunicamycin. J Biol Chem 2011; 286:29127-38; PMID:21676868; http://dx.doi.org/10.1074/jbc.M110.169771
100. Yadav B, Taurin S, Larsen L, Rosengren RJ. RL66 a second-generation curcumin analog has potent in vivo and in vitro anticancer activity in ERnegative breast cancer models. Int J Oncol 2012; 41:1723-32; PMID:22971638
101. Sunwoo JB, Chen Z, Dong G, Yeh N, Crowl Bancroft C, Sausville E, Adams J, Elliott P, Van Waes C. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res 2001; 7:1419-28; PMID:11350913
102. Politou M, Naresh K, Terpos E, Crawley D, Lampert I, Apperley JF, Rahemtulla A. Anti-angiogenic effect of bortezomib in patients with multiple myeloma. Acta haematol 2005; 114:170-3; PMID:16227683; http://dx.doi.org/10.1159/000087894
103. Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer 2012; 12:860-75; PMID:23151605; http://dx.doi.org/10.1038/nrc3380
104. Lee HB, Ho AS, Teo SH. p53 Status does not affect photodynamic cell killing induced by hypericin. Cancer Chemother Pharmacol 2006; 58:91-8; PMID:16211395; http://dx.doi.org/10.1007/s00280-005-0131-3
105. Stavridi ES, Halazonetis TD. p53 and stress in the ER. Genes Dev 2004; 18:241-4; PMID:14871924; http://dx.doi.org/10.1101/gad.1181704
106. Li X, Zhang K, Li Z. Unfolded protein response in cancer: the physician's perspective. J Hematol Oncol 2011; 4:8; PMID:21345215; http://dx.doi.org/10.1186/1756-8722-4-8
107. Maes H, Rubio N, Garg AD, Agostinis P. Autophagy: shaping the tumor microenvironment and therapeutic response. Trends Mol Med 2013; 19:428-46; PMID:23714574; http://dx.doi.org/10.1016/j.molmed.2013.04.005
108. Deegan S, Saveljeva S, Gorman AM, Samali A. Stress-induced self-cannibalism: on the regulation of autophagy by endoplasmic reticulum stress. Cell Mol Life Sci 2013; 70:2425-41; PMID:23052213; http://dx.doi.org/10.1007/s00018-012-1173-4
109. Luyckx A, De Somer L, Rutgeerts O, Waer M, Verfaillie CM, Van Gool S, Billiau AD. Mouse MAPC-mediated immunomodulation: Cell-line dependent variation. Exp Hematol 2010; 38:1-2; PMID:19853014; http://dx.doi.org/10.1016/j.exphem.2009.10.009
110. Park MA, Zhang G, Martin AP, Hamed H, Mitchell C, Hylemon PB, Graf M, Rahmani M, Ryan K, Liu X, et al. Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation. Cancer Biol Ther 2008; 7:1648-62; PMID:18787411; http://dx.doi.org/10.4161/cbt.7.10.6623
111. Zhou Y, Liang X, Chang H, Shu F, Wu Y, Zhang T, Fu J, Zhang Q, Zhu J, Mi M. Ampelopsin-induced autophagy protects breast cancer cells from apoptosis through Akt-mTOR pathway via ER stress. Cancer Sci 2014; 105(10):1279-87; PMID:25088800
112. Wang Z, Jiang C, Chen W, Zhang G, Luo D, Cao Y, Wu J, Ding Y, Liu B. Baicalein induces apoptosis and autophagy via endoplasmic reticulum stress in hepatocellular carcinoma cells. BioMed Res Int 2014; 2014:732516; PMID:24995326
113. Bellodi C, Lidonnici MR, Hamilton A, Helgason GV, Soliera AR, Ronchetti M, Galavotti S, Young KW, Selmi T, Yacobi R, et al. Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. J Clin Invest 2009; 119:1109-23; PMID:19363292; http://dx.doi.org/10.1172/JCI35660
114. Chow SE, Kao CH, Liu YT, Cheng ML, Yang YW, Huang YK, Hsu CC, Wang JS. Resveratrol induced ER expansion and ER caspase-mediated apoptosis in human nasopharyngeal carcinoma cells. Apoptosis 2014; 19:527-41; PMID:24264887; http://dx.doi.org/10.1007/s10495-013-0945-0
115. Song L, Liu H, Ma L, Zhang X, Jiang Z, Jiang C. Inhibition of autophagy by 3-MA enhances endoplasmic reticulum stress-induced apoptosis in human nasopharyngeal carcinoma cells. Oncol Lett 2013; 6:1031-8; PMID:24137459
116. Granato M, Santarelli R, Lotti LV, Di Renzo L, Gonnella R, Garufi A, Trivedi P, Frati L, D'Orazi G, Faggioni A, et al. JNK and macroautophagy activation by bortezomib has a pro-survival effect in primary effusion lymphoma cells. PLoS One 2013; 8:e75965
117. Qu W, Xiao J, Zhang H, Chen Q, Wang Z, Shi H, Gong L, Chen J, Liu Y, Cao R, et al. B19, a novel monocarbonyl analogue of curcumin, induces human ovarian cancer cell apoptosis via activation of endoplasmic reticulum stress and the autophagy signaling pathway. IntJ Biol Sci 2013; 9:766-77; PMID:23983610; http://dx.doi.org/10.7150/ijbs.5711
118. Salazar M, Carracedo A, Salanueva IJ, Hernandez-Tiedra S, Lorente M, Egia A, Vazquez P, Blazquez C, Torres S, Garcia S, et al. Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells. J Clin Invest 2009; 119:1359-72; PMID:19425170; http://dx.doi.org/10.1172/JCI37948
119. Gills JJ, Lopiccolo J, Dennis PA. Nelfinavir, a new anti-cancer drug with pleiotropic effects and many paths to autophagy. Autophagy 2008; 4:107-9; PMID:18000394; http://dx.doi.org/10.4161/auto.5224
120. Rubiolo JA, Lopez-Alonso H, Martinez P, Millan A, Cagide E, Vieytes MR, Vega FV, Botana LM. Yessotoxin induces Er-stress followed by autophagic cell death in glioma cells mediated by mTOR and BNIP3. Cell Aignal 2013; PMID:24514040
121. Ding WX, Ni HM, Gao W, Hou YF, Melan MA, Chen X, Stolz DB, Shao ZM, Yin XM. Differential effects of endoplasmic reticulum stress-induced autophagy on cell survival. J Biol Chem 2007; 282:4702-10; PMID:17135238; http://dx.doi.org/10.1074/jbc.M609267200
122. Armstrong JL, Corazzari M, Martin S, Pagliarini V, Falasca L, Hill DS, Ellis N, Al Sabah S, Redfern CP, Fimia GM, et al. Oncogenic B-RAF signaling in melanoma impairs the therapeutic advantage of autophagy inhibition. Clin Cancer Res 2011; 17:2216-26; PMID:21270111; http://dx.doi.org/10.1158/1078-0432.CCR-10-3003
123. Garg AD, Dudek AM, Ferreira GB, Verfaillie T, Vandenabeele P, Krysko DV, Mathieu C, Agostinis P. ROS-induced autophagy in cancer cells assists in evasion from determinants of immunogenic cell death. Autophagy 2013; 9:1292-307; PMID:23800749; http://dx.doi.org/10.4161/auto.25399
124. Feng YX, Sokol ES, Del Vecchio CA, Sanduja S, Claessen JH, Proia TA, Jin DX, Reinhardt F, Ploegh HL, Wang Q, et al. Epithelial-to-mesenchymal transition activates PERK-eIF2alpha and sensitizes cells to endoplasmic reticulum stress. Cancer Discov 2014; 4:702-15; PMID:24705811; http://dx.doi.org/10.1158/2159-8290.CD-13-0945
125. Tseng CN, Huang CF, Cho CL, Chang HW, Huang CW, Chiu CC, Chang YF. Brefeldin a effectively inhibits cancer stem cell-like properties and MMP-9 activity in human colorectal cancer Colo 205 cells. Molecules 2013; 18:10242-53; PMID:23973996; http://dx.doi.org/10.3390/molecules180910242
126. Du HY, Olivo M, Mahendran R, Huang Q, Shen HM, Ong CN, Bay BH. Hypericin photoactivation triggers down-regulation of matrix metalloproteinase-9 expression in well-differentiated human nasopharyngeal cancer cells. Cell Mol Life Sci 2007; 64:979-88; PMID:17385073; ttp://dx.doi.org/10.1007/s00018-007-7030-1
127. Chen CH, Chen WY, Lin SF, Wong RJ. Epithelial-mesenchymal transition enhances response to oncolytic herpesviral therapy through nectin-1. Human Gene Therapy 2014; 25:539-51; PMID:24568312; http://dx.doi.org/10.1089/hum.2013.177
128. Ulianich L, Garbi C, Treglia AS, Punzi D, Miele C, Raciti GA, Beguinot F, Consiglio E, Di Jeso B. ER stress is associated with dedifferentiation and an epithelial-to-mesenchymal transition-like phenotype in PC Cl3 thyroid cells. J Cell Sci 2008; 121:477-86; PMID:18211961; http://dx.doi.org/10.1242/jcs.017202
129. Moon SY, Kim HS, Nho KW, Jang YJ, Lee SK. Endoplasmic reticulum stress induces epithelial-mesenchymal transition through autophagy via activation of c-src kinase. Nephron Exp Nephrol 2014; 126:127-40; PMID:24863135; http://dx.doi.org/10.1159/000362457
130. Zhong Q, Zhou B, Ann DK, Minoo P, Liu Y, Banfalvi A, Krishnaveni MS, Dubourd M, Demaio L, Willis BC, et al. Role of endoplasmic reticulum stress in epithelial-mesenchymal transition of alveolar epithelial cells: effects of misfolded surfactant protein. Am J Respir Cell Mol Biol 2011; 45:498-509; PMID:21169555; http://dx.doi.org/10.1165/rcmb.2010-0347OC
131. Kim YH, Jung JC. Suppression of tunicamycin-induced CD44v6 ectodomain shedding and apoptosis is correlated with temporal expression patterns of active ADAM10, MMP-9 and MMP-13 proteins in Caki-2 renal carcinoma cells. Oncol Rep 2012; 28:1869-74; PMID:22923171
132. Zhao H, Wu QQ, Cao LF, Qing HY, Zhang C, Chen YH, Wang H, Liu RR, Xu DX. Melatonin inhibits endoplasmic reticulum stress and epithelial-mesenchymal transition during bleomycin-induced pulmonary fibrosis in mice. PLoS One 2014; 9:e97266
133. Schafer S, Weibel S, Donat U, Zhang Q, Aguilar RJ, Chen NG, Szalay AA. Vaccinia virus-mediated intra-tumoral expression of matrix metalloproteinase 9 enhances oncolysis of PC-3 xenograft tumors. BMC Cancer 2012; 12:366; PMID:22917220; http://dx.doi.org/10.1186/1471-2407-12-366
134. Hong CS, Fellows W, Niranjan A, Alber S, Watkins S, Cohen JB, Glorioso JC, Grandi P. Ectopic matrix metalloproteinase-9 expression in human brain tumor cells enhances oncolytic HSV vector infection. Gene Ther 2010; 17:1200-5; PMID:20463757; http://dx.doi.org/10.1038/gt.2010.66
135. Mahller YY, Vaikunth SS, Ripberger MC, Baird WH, Saeki Y, Cancelas JA, Crombleholme TM, Cripe TP. Tissue inhibitor of metalloproteinase-3 via oncolytic herpesvirus inhibits tumor growth and vascular progenitors. Cancer Res 2008; 68:1170-9; PMID:18281493; http://dx.doi.org/10.1158/0008-5472.CAN-07-2734
136. Wang X, Eno CO, Altman BJ, Zhu Y, Zhao G, Olberding KE, Rathmell JC, Li C. ER stress modulates cellular metabolism. Biochem J 2011; 435:285-96; PMID:21241252; http://dx.doi.org/10.1042/BJ20101864
137. Rysman E, Brusselmans K, Scheys K, Timmermans L, Derua R, Munck S, Van Veldhoven PP, Waltregny D, Daniels VW, Machiels J, et al. De novo lipogenesis protects cancer cells from free radicals and chemotherapeutics by promoting membrane lipid saturation. Cancer Res 2010; 70:8117-26; PMID:20876798; http://dx.doi.org/10.1158/0008-5472.CAN-09-3871
138. Wise DR, Thompson CB. Glutamine addiction: a new therapeutic target in cancer. Trends Biochem Sci 2010; 35:427-33; PMID:20570523; http://dx.doi.org/10.1016/j.tibs.2010.05.003
139. Jones RG, Thompson CB. Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes Dev 2009; 23:537-48; PMID:19270154; http://dx.doi.org/10.1101/gad.1756509
140. Guan BJ, Krokowski D, Majumder M, Schmotzer CL, Kimball SR, Merrick WC, Koromilas AE, Hatzoglou M. Translational control during endoplasmic reticulum stress beyond phosphorylation of the translation initiation factor eIF2alpha. J Biol Chem 2014; 289:12593-611; PMID:24648524; http://dx.doi.org/10.1074/jbc.M113.543215
141. El Mjiyad N, Caro-Maldonado A, Ramirez-Peinado S, Munoz-Pinedo C. Sugar-free approaches to cancer cell killing. Oncogene 2011; 30:253-64; PMID:20972457; http://dx.doi.org/10.1038/onc.2010.466
142. Kawakami T, Yoshimi M, Kadota Y, Inoue M, Sato M, Suzuki S. Prolonged endoplasmic reticulum stress alters placental morphology and causes low birth weight. Toxicol Appl Pharmacol 2014; 275:134-44; PMID:24370435; http://dx.doi.org/10.1016/j.taap.2013.12.008
143. Ferrer CM, Lynch TP, Sodi VL, Falcone JN, Schwab LP, Peacock DL, Vocadlo DJ, Seagroves TN, Reginato MJ. O-GlcNAcylation regulates cancer metabolism and survival stress signaling via regulation of the HIF-1 pathway. Mol Cell 2014; 54:820-31; PMID:24857547; http://dx.doi.org/10.1016/j.molcel.2014.04.026
144. Mendez-Lucas A, Hyrossova P, Novellasdemunt L, Vinals F, Perales JC. Mitochondrial phosphoenolpyruvate carboxykinase (PEPCK-M) is a pro-survival, endoplasmic reticulum (ER) stress response gene involved in tumor cell adaptation to nutrient availability. J Biol Chem 2014; 289:22090-102; PMID:24973213; http://dx.doi.org/10.1074/jbc.M114.566927
145. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010; 140:883-99; PMID:20303878; http://dx.doi.org/10.1016/j.cell.2010.01.025
146. Grivennikov SI, Karin M. Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage. Ann Rheum Dis 2011; 70 Suppl 1:i104-8; PMID:21339211; http://dx.doi.org/10.1136/ard.2010.140145
147. Nakagawa H, Umemura A, Taniguchi K, Font-Burgada J, Dhar D, Ogata H, Zhong Z, Valasek MA, Seki E, Hidalgo J, et al. ER stress cooperates with hypernutrition to trigger TNF-dependent spontaneous HCC development. Cancer cell 2014; 26:331-43; PMID:25132496; http://dx.doi.org/10.1016/j.ccr.2014.07.001
148. Mahadevan NR, Rodvold J, Sepulveda H, Rossi S, Drew AF, Zanetti M. Transmission of endoplasmic reticulum stress and pro-inflammation from tumor cells to myeloid cells. Proc Natl Acad Sci U S A 2011; 108:6561-6; PMID:21464300; http://dx.doi.org/10.1073/pnas.1008942108
149. Ma Y, Conforti R, Aymeric L, Locher C, Kepp O, Kroemer G, Zitvogel L. How to improve the immunogenicity of chemotherapy and radiotherapy. Cancer Metastasis Rev 2011; 30:71-82; PMID:21298323; http://dx.doi.org/10.1007/s10555-011-9283-2
150. Zitvogel L, Kepp O, Kroemer G. Decoding cell death signals in inflammation and immunity. Cell 2010; 140:798-804; PMID:20303871; http://dx.doi.org/10.1016/j.cell.2010.02.015
151. Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C, Vermaelen K, Panaretakis T, Mignot G, Ullrich E, et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 2009; 15:1170-8; PMID:19767732; http://dx.doi.org/10.1038/nm.2028
152. Garg AD, Dudek AM, Agostinis P. Calreticulin surface exposure is abrogated in cells lacking, chaperone-mediated autophagy-essential gene, LAMP2A. Cell Death Dis 2013; 4:e826; PMID:24091669; http://dx.doi.org/10.1038/cddis.2013.372
153. Michaud M, Martins I, Sukkurwala AQ, Adjemian S, Ma Y, Pellegatti P, Shen S, Kepp O, Scoazec M, Mignot G, et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 2011; 334:1573-7; PMID:22174255; http://dx.doi.org/10.1126/science.1208347
154. Braumuller H, Wieder T, Brenner E, Assmann S, Hahn M, Alkhaled M, Schilbach K, Essmann F, Kneilling M, Griessinger C, et al. T-helper-1-cell cytokines drive cancer into senescence. Nature 2013; 494:361-5; PMID:23376950; http://dx.doi.org/10.1038/nature11824
155. Garg AD, Martin S, Golab J, Agostinis P. Danger signalling during cancer cell death: origins, plasticity and regulation. Cell Death Differ 2014; 21:26-38; PMID:23686135; http://dx.doi.org/10.1038/cdd.2013.48
156. Firczuk M, Gabrysiak M, Barankiewicz J, Domagala A, Nowis D, Kujawa M, Jankowska-Steifer E, Wachowska M, Glodkowska-Mrowka E, Korsak B, et al. GRP78-targeting subtilase cytotoxin sensitizes cancer cells to photodynamic therapy. Cell Death Dis 2013; 4:e741; PMID:23887632; http://dx.doi.org/10.1038/cddis.2013.265
157. Vacchelli E, Eggermont A, Sautes-Fridman C, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Oncolytic viruses for cancer therapy. Oncoimmunology 2013; 2:e24612; PMID:23894720; http://dx.doi.org/10.4161/onci.24612
158. Xu S, Sankar S, Neamati N. Protein disulfide isomerase: a promising target for cancer therapy. Drug Discov Today 2014; 19:222-40; PMID:24184531; http://dx.doi.org/10.1016/j.drudis.2013.10.017
159. Agostinis P, Berg K, Cengel KA, Foster TH, Girotti AW, Gollnick SO, Hahn SM, Hamblin MR, Juzeniene A, Kessel D, et al. Photodynamic therapy of cancer: an update. CA Cancer J Clin 2011; 61:250-81; PMID:21617154; http://dx.doi.org/10.3322/caac.20114
160. Antonarakis ES, Carducci MA. Future directions in castrate-resistant prostate cancer therapy. Clin Genitourin Cancer 2010; 8:37-46; PMID:21208854; http://dx.doi.org/10.3816/CGC.2010.n.006
161. 2+ pump inhibitors. Biochem Soc Trans 2011; 39:789-97; PMID:21599650
162. Park HR, Tomida A, Sato S, Tsukumo Y, Yun J, Yamori T, Hayakawa Y, Tsuruo T, Shin-ya K. Effect on tumor cells of blocking survival response to glucose deprivation. J Natl Cancer Inst 2004; 96:1300-10; PMID:15339968; http://dx.doi.org/10.1093/jnci/djh243
163. Xi H, Barredo JC, Merchan JR, Lampidis TJ. Endoplasmic reticulum stress induced by 2-deoxyglucose but not glucose starvation activates AMPK through CaMKKbeta leading to autophagy. Biochem Pharmacol 2013; 85:1463-77; PMID:23500541; http://dx.doi.org/10.1016/j.bcp.2013.02.037
164. Garrido G, Rabasa A, Sanchez B, Lopez MV, Blanco R, Lopez A, Hernandez DR, Perez R, Fernandez LE. Induction of immunogenic apoptosis by blockade of epidermal growth factor receptor activation with a specific antibody. J Immunol 2011; 187:4954-66; PMID:21984704; http://dx.doi.org/10.4049/jimmunol.1003477
165. Apetoh L, Mignot G, Panaretakis T, Kroemer G, Zitvogel L. Immunogenicity of anthracyclines: moving towards more personalized medicine. Trends Mol Med 2008; 14:141-51; PMID:18353726; http://dx.doi.org/10.1016/j.molmed.2008.02.002
166. Reinert T, Baldotto CSdR, Nunes FAP, Scheliga AAdS. Bleomycin-induced lung injury. J Cancer Res 2013; 2013:9; http://dx.doi.org/10.1155/2013/480608
167. Crawford LJ, Walker B, Irvine AE. Proteasome inhibitors in cancer therapy. J Cell Commun Signal 2011; 5:101-10; PMID:21484190; http://dx.doi.org/10.1007/s12079-011-0121-7
168. Beck D, Niessner H, Smalley KS, Flaherty K, Paraiso KH, Busch C, Sinnberg T, Vasseur S, Iovanna JL, Driessen S, et al. Vemurafenib potently induces endoplasmic reticulum stress-mediated apoptosis in BRAFV600E melanoma cells. Sci Signal 2013; 6:ra7; PMID:23362240; http://dx.doi.org/10.1126/scisignal.2003057
169. Guzman M, Duarte MJ, Blazquez C, Ravina J, Rosa MC, Galve-Roperh I, Sanchez C, Velasco G, Gonzalez-Feria L. A pilot clinical study of Delta9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br J Cancer 2006; 95:197-203; PMID:16804518; http://dx.doi.org/10.1038/sj.bjc.6603236
170. Brozovic A, Vukovic L, Polancac DS, Arany I, Koberle B, Fritz G, Fiket Z, Majhen D, Ambriovic-Ristov A, Osmak M. Endoplasmic reticulum stress is involved in the response of human laryngeal carcinoma cells to Carboplatin but is absent in Carboplatin-resistant cells. PLoS One 2013; 8:e76397; PMID:24086737; http://dx.doi.org/10.1371/journal.pone.0076397
171. Kepp O, Menger L, Vacchelli E, Adjemian S, Martins I, Ma Y, Sukkurwala AQ, Michaud M, Galluzzi L, Zitvogel L, et al. Anticancer activity of cardiac glycosides: At the frontier between cell-autonomous and immunological effects. Oncoimmunology 2012; 1:1640-2; PMID:23264921; http://dx.doi.org/10.4161/onci.21684
172. Kardosh A, Golden EB, Pyrko P, Uddin J, Hofman FM, Chen TC, Louie SG, Petasis NA, Schonthal AH. Aggravated endoplasmic reticulum stress as a basis for enhanced glioblastoma cell killing by bortezomib in combination with celecoxib or its non-coxib analogue, 2,5-dimethyl-celecoxib. Cancer Res 2008; 68:843-51; PMID:18245486; http://dx.doi.org/10.1158/0008-5472.CAN-07-5555
173. Wang L, Song R, Shen Y, Sun Y, Gu Y, Shu Y, Xu Q. Targeting sarcoplasmic/endoplasmic reticulum Ca(2)+-ATPase 2 by curcumin induces ER stress-associated apoptosis for treating human liposarcoma. Mol Cancer Ther 2011; 10:461-71; PMID:21282356; http://dx.doi.org/10.1158/1535-7163.MCT-10-0812
174. Teiten MH, Eifes S, Dicato M, Diederich M. Curcumin-the paradigm of a multi-target natural compound with applications in cancer prevention and treatment. Toxins (Basel) 2010; 2:128-62; PMID:22069551; http://dx.doi.org/10.3390/toxins2010128
175. Emadi A, Jones RJ, Brodsky RA. Cyclophosphamide and cancer: golden anniversary. Nat Rev Clin Oncol 2009; 6:638-47; PMID:19786984; http://dx.doi.org/10.1038/nrclinonc.2009.146
176. Valdez BC, Zander AR, Song G, Murray D, Nieto Y, Li Y, Champlin RE, Andersson BS. Synergistic cytotoxicity of gemcitabine, clofarabine and edelfosine in lymphoma cell lines. Blood Cancer J 2014; 4:e171; PMID:24413065
177. Magnaghi P, D'Alessio R, Valsasina B, Avanzi N, Rizzi S, Asa D, Gasparri F, Cozzi L, Cucchi U, Orrenius C, et al. Covalent and allosteric inhibitors of the ATPase VCP/p97 induce cancer cell death. Nat Chem Biol 2013; 9:548-56; PMID:23892893; http://dx.doi.org/10.1038/nchembio.1313
178. Glaser KB. HDAC inhibitors: clinical update and mechanism-based potential. Biochem Pharmacol 2007; 74:659-71; PMID:17498667; http://dx.doi.org/10.1016/j.bcp.2007.04.007
179. Kahali S, Sarcar B, Fang B, Williams ES, Koomen JM, Tofilon PJ, Chinnaiyan P. Activation of the unfolded protein response contributes toward the antitumor activity of vorinostat. Neoplasia 2010; 12:80-6; PMID:20072656
180. Fucikova J, Moserova I, Truxova I, Hermanova I, Vancurova I, Partlova S, Fialova A, Sojka L, Cartron PF, Houska M, et al. High hydrostatic pressure induces immunogenic cell death in human tumor cells. Int J Cancer 2014; 135:1165-77; PMID:24500981; http://dx.doi.org/10.1002/ijc.28766
181. Jhaveri K, Taldone T, Modi S, Chiosis G. Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers. Biochim Biophys Acta 2012; 1823:742-55; PMID:22062686; http://dx.doi.org/10.1016/j.bbamcr.2011.10.008
182. Taeger G, Grabellus F, Podleska LE, Muller S, Ruchholtz S. Effectiveness of regional chemotherapy with TNF-alpha/melphalan in advanced soft tissue sarcoma of the extremities. Int J Hyperthermia 2008; 24:193-203; PMID:18392998; http://dx.doi.org/10.1080/02656730701868387
183. Voron T, Zinzindohoue F, Journois D, Herve C, Ponzio O, Lucas N. Hyperthermic isolated liver perfusion with melphalan and bevacizumab. J Visc Surg 2013; 150:60-6; PMID:23182850
184. van Iersel LB, Koopman M, van de Velde CJ, Mol L, van Persijn van Meerten EL, Hartgrink HH, Kuppen PJ, Vahrmeijer AL, Nortier JW, Tollenaar RA, et al. Management of isolated nonresectable liver metastases in colorectal cancer patients: a case-control study of isolated hepatic perfusion with melphalan versus systemic chemotherapy. Ann Oncol 2010; 21:1662-7; PMID:20110289; http://dx.doi.org/10.1093/annonc/mdp589
185. Alexander HR, Jr., Libutti SK, Pingpank JF, Steinberg SM, Bartlett DL, Helsabeck C, Beresneva T. Hyperthermic isolated hepatic perfusion using melphalan for patients with ocular melanoma metastatic to liver. Clin Cancer Res 2003; 9:6343-9; PMID:14695133
186. Parker AL, Kavallaris M, McCarroll JA. Microtubules and their role in cellular stress in cancer. Front Oncol 2014; 4:153; PMID:24995158; http://dx.doi.org/10.3389/fonc.2014.00153
187. Dumontet C, Jordan MA. Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov 2010; 9:790-803; PMID:20885410; http://dx.doi.org/10.1038/nrd3253
188. Mayer RJ. Oxaliplatin as part of adjuvant therapy for colon cancer: more complicated than once thought. J Clin Oncol 2012; 30:3325-7; PMID:22915653; http://dx.doi.org/10.1200/JCO.2012.44.1949
189. Baskar R, Lee KA, Yeo R, Yeoh KW. Cancer and radiation therapy: current advances and future directions. Int J Med Sci 2012; 9:193-9; PMID:22408567; http://dx.doi.org/10.7150/ijms.3635
190. Chen J, Xie J, Jiang Z, Wang B, Wang Y, Hu X. Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2. Oncogene 2011; 30:4297-306; PMID:21516121; http://dx.doi.org/10.1038/onc.2011.137
191. Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, Schwartz B, Simantov R, Kelley S. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006; 5:835-44; PMID:17016424; http://dx.doi.org/10.1038/nrd2130